These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7833096)

  • 1. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
    Buccheri G; Ferrigno D
    Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Rosso A
    Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
    Buccheri G; Ferrigno D
    Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
    Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
    Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II study.
    Salvati F; Antilli A; Cruciani AR; Lombardi A; Mugnaini L; Nunziati F; Perrone N; Portalone L; Signora M
    Tumori; 1995; 81(1):48-51. PubMed ID: 7754542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
    Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
    Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients.
    Buccheri G; Ferrigno D; Vola F; Curcio A
    Oncology; 1989; 46(4):212-6. PubMed ID: 2544837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
    Chahinian AP; Propert KJ; Ware JH; Zimmer B; Perry MC; Hirsh V; Skarin A; Kopel S; Holland JF; Comis RL
    J Clin Oncol; 1989 Aug; 7(8):993-1002. PubMed ID: 2547030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.
    Morton RF; Jett JR; McGinnis WL; Earle JD; Therneau TM; Krook JE; Elliott TE; Mailliard JA; Nelimark RA; Maksymiuk AW
    Ann Intern Med; 1991 Nov; 115(9):681-6. PubMed ID: 1656827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
    Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
    Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in pulmonary surfactant composition following MACC chemotherapy for lung carcinoma.
    Rossi GA; Balbi B; Benatti U; Morelli A; Sacco O; Vassallo F; Ravazzoni C
    Eur J Respir Dis; 1987 Nov; 71(5):400-9. PubMed ID: 2832202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study.
    Buccheri GF; Ferrigno D; Curcio A; Vola F; Rosso A
    Cancer; 1989 Feb; 63(3):428-32. PubMed ID: 2536288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
    Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
    J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
    J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
    Robinson E; Haim N; Segal R; Veseley Z; Mekori T
    Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
    Colella E; Merlano M; Blengio F; Angelini F; Ausili Cefaro GP; Scasso F; Lo Russo V; Cirulli S; Giannarelli D; Cognetti F
    Eur J Cancer; 1994; 30A(7):928-30. PubMed ID: 7946585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.